L-alpha-天冬氨酰-L-缬氨酸 | 13433-04-0

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-alpha-天冬氨酰-L-缬氨酸
• 英文名称: N-α-L-aspartyl-L-valine
• 英文别名: Asp-Val；N-L-α-aspartyl-L-valine；N-L-α-Aspartyl-L-valin；L-α-Aspartyl=>L-valin；L-aspartyl-L-valine；(2S)-2-[[(2S)-2-amino-3-carboxypropanoyl]amino]-3-methylbutanoic acid
• CAS: 13433-04-0
• 化学式: C₉H₁₆N₂O₅
• 分子量: 232.236
• InChiKey: CPMKYMGGYUFOHS-FSPLSTOPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  130
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2924199090

反应信息

• 作为反应物：
  描述：

  L-alpha-天冬氨酰-L-缬氨酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 27.67h， 生成
  参考文献：
  名称：

  由手性胶凝剂的组装引发的新型聚集诱导的发射增强：从非发射性纳米纤维到发射性微环

  摘要：

  在这项研究中，描述了由手性胶凝剂的自组装触发的新型聚集诱导发射（AIE）增强。分子手性的原位调节可触发显示出...

  DOI：

  10.1039/c6cc08808b
• 作为产物：
  描述：

  N-(N-benzyloxycarbonyl-L-α-aspartyl)-L-valine methyl ester 在 sodium hydroxide 作用下， 生成 L-alpha-天冬氨酰-L-缬氨酸
  参考文献：
  名称：

  氨基酸和多肽。第十二部分。α-和β-L-天冬氨酰-L-缬氨酸

  摘要：

  DOI：

  10.1039/jr9540002870

文献信息

• Transport and Metabolic Pathway of Thymocartin (TP4) in Excised Bovine Nasal Mucosa
  作者：Steffen Lang、Peter Langguth、Rainer Oschmann、Birgit Traving、Hans P Merkle

  DOI：10.1111/j.2042-7158.1996.tb03919.x

  日期：2011.4.12

  Thymocartin (TP4, Arg-Lys-Asp-Val) is the 32–35 fragment of the naturally occuring thymic factor (thymopoietin). Here studies on the nasal transport and metabolism of TP4 were performed. Freshly excised bovine nasal mucosa was taken as a model membrane. For permeation studies typical donor-receiver experiments (side-by-side) and finite-dose experiments with small volumes of highly concentrated solutions were carried out.

  The metabolic pathway of TP4 in nasal mucosa was found to occur according to a typical aminopeptidase cleavage pattern, stepwise forming Lys-Asp-Val and Asp-Val. TP4 metabolism experiments under reflection kinetics showed a saturation profile above 0.5 μmol mL−1. A non-linear kinetic model consisting of three steps in sequence was sufficient to describe the kinetics: for the first step saturable Michaelis-Meat kinetics, and for the second and the third step first-order kinetics were assured. The model was capable of simultaneously fitting the data for the full range of initial concentrations from 0.1 up to 1.0 μmol mL−1. Saturation kinetics was also found to be the prominent feature of the permeation experiments performed. In the lower concentration range (<0.4 μmol mL−1), transport of TP4 across nasal mucosa was controlled by metabolism, in the higher concentration range (>0.85 μmol mL−1) diffusion control became more important.

  We conclude that enhancement of absorption can be achieved when nasal aminopeptidases are saturated, e.g. at high TP4 concentrations.

  摘要：Thymocartin（TP4，Arg-Lys-Asp-Val）是天然存在的胸腺因子（胸腺生成素）的32-35片段。本研究对TP4在鼻腔的转运和代谢进行了研究。新鲜切除的牛鼻黏膜被用作模型膜。对于渗透研究，进行了典型的供体-受体实验（并置）和用高浓度溶液的小体积进行的有限剂量实验。 在鼻黏膜中，TP4的代谢途径被发现符合典型的氨基肽酶裂解模式，逐步形成Lys-Asp-Val和Asp-Val。在反射动力学下进行的TP4代谢实验显示，在0.5 μmol mL−1以上存在饱和曲线。一个由三个步骤组成的非线性动力学模型足以描述这些动力学：对于第一步饱和的Michaelis-Menten动力学，对于第二步和第三步，确保了一阶动力学。该模型能够同时拟合从0.1到1.0 μmol mL−1的初始浓度范围的数据。饱和动力学也被发现是渗透实验的显著特征。在较低浓度范围（小于0.4 μmol mL−1）内，TP4在鼻黏膜上的转运受代谢控制，在较高浓度范围（大于0.85 μmol mL−1）内，扩散控制变得更为重要。 我们得出结论，当鼻氨基肽酶饱和时，例如在高TP4浓度下，可以实现吸收的增强。
• DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1941896A1

  公开（公告）日：2008-07-09

  The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula:         X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.

  本发明提供了一种口服组合物，它包含至少一种由式表示的二肽： X-Y (其中 X 代表丙氨酰、甘氨酰、精氨酰、丝氨酰、α-天冬氨酰或α-谷氨酰，Y 代表缬氨酸、亮氨酸或异亮氨酸），其目的是提供一种营养、药效和口感俱佳的口服组合物，该组合物至少包含一种选自缬氨酸、亮氨酸和异亮氨酸的二肽、或提供一种口服组合物，该组合物在加工特性（如溶解性和压片性能）方面非常出色，并包含至少一种选自缬氨酸、亮氨酸和异亮氨酸的成分。
• Dipeptide-Comprising Composition for Oral Administration
  申请人：Sakai Yasushi

  公开号：US20080305151A1

  公开（公告）日：2008-12-11

  The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula: X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.
• US7846902B2
  申请人：——

  公开号：US7846902B2

  公开（公告）日：2010-12-07
• A novel aggregation-induced emission enhancement triggered by the assembly of a chiral gelator: from non-emissive nanofibers to emissive micro-loops
  作者：Wenrui Chen、Guangyan Qing、Taolei Sun

  DOI：10.1039/c6cc08808b

  日期：——

  In this study, a novel aggregation-induced emission (AIE) enhancement triggered by the self-assembly of chiral gelator is described. Tuning of molecular chirality in situ triggers different assemblies of superstructures exhibiting...

  在这项研究中，描述了由手性胶凝剂的自组装触发的新型聚集诱导发射（AIE）增强。分子手性的原位调节可触发显示出...